Bicycle Therapeutics Plc

( )
BCYC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 0.43%74.991.0%$1746.30m
AMGNAmgen, Inc. 4.99%219.191.3%$931.17m
REGNRegeneron Pharmaceuticals, Inc. 2.16%512.332.6%$846.25m
BIIBBiogen, Inc. 5.23%316.951.5%$805.69m
VRTXVertex Pharmaceuticals, Inc. 0.80%249.661.9%$657.48m
MRNAModerna, Inc. 1.25%32.420.0%$510.65m
ILMNIllumina, Inc. 0.13%280.993.5%$491.81m
ALXNAlexion Pharmaceuticals, Inc. 4.05%98.562.0%$309.13m
AAgilent Technologies, Inc. 3.58%76.681.6%$228.40m
INCYIncyte Corp. 1.26%87.752.5%$221.05m
EXASEXACT Sciences Corp. 6.02%66.3721.0%$182.14m
SGENSeattle Genetics, Inc. -1.80%119.686.1%$161.30m
BMRNBioMarin Pharmaceutical, Inc. -0.29%79.604.3%$150.56m
NVAXNovavax, Inc. 15.30%17.18114.7%$135.65m
IMMUImmunomedics, Inc. -2.54%18.4311.9%$121.13m

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.